it's true there are a lot of variables, but I think most of the downside is already priced in
big pharma is trading at very low multiples now, and the dividend yields are awesome
with an aging population and a lot of health-care expansion in developing countries, I think there is a lot of room to grow
definitely some concern stateside, but these copanies have plenty of other people to sell to. Asia comes to mind. |